{"Title": "A genetic model of ivabradine recapitulates results from randomized clinical trials", "Year": 2020, "Source": "PLoS ONE", "Volume": "15", "Issue": 7, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 1, "DOI": "10.1371/journal.pone.0236193", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85088500384&origin=inward", "Abstract": "\u00a9 2020 Legault et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Background Naturally occurring human genetic variants provide a valuable tool to identify drug targets and guide drug prioritization and clinical trial design. Ivabradine is a heart rate lowering drug with protective effects on heart failure despite increasing the risk of atrial fibrillation. In patients with coronary artery disease without heart failure, the drug does not protect against major cardiovascular adverse events prompting questions about the ability of genetics to have predicted those effects. This study evaluates the effect of a variant in HCN4, ivabradine\u2019s drug target, on safety and efficacy endpoints. Methods We used genetic association testing and Mendelian randomization to predict the effect of ivabradine and heart rate lowering on cardiovascular outcomes. Results Using data from the UK Biobank and large GWAS consortia, we evaluated the effect of a heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine\u2019s drug target. These genetic association analyses showed increases in risk for atrial fibrillation (OR 1.09, 95% CI: 1.06\u20131.13, P = 9.3 \u00d710\u22129) in the UK Biobank. In a cause-specific competing risk model to account for the increased risk of atrial fibrillation, the HCN4 variant reduced incident heart failure in participants that did not develop atrial fibrillation (HR 0.90, 95% CI: 0.83\u20130.98, P = 0.013). In contrast, the same heart rate reducing HCN4 variant did not prevent a composite endpoint of myocardial infarction or cardiovascular death (OR 0.99, 95% CI: 0.93\u20131.04, P = 0.61). Conclusion Genetic modelling of ivabradine recapitulates its benefits in heart failure, promotion of atrial fibrillation, and neutral effect on myocardial infarction.", "AuthorKeywords": null, "IndexKeywords": ["Adult", "Aged", "Alleles", "Cardiovascular Diseases", "Endpoint Determination", "Female", "Genetic Variation", "Genome-Wide Association Study", "Heart Rate", "Humans", "Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels", "Ivabradine", "Male", "Mendelian Randomization Analysis", "Middle Aged", "Models, Genetic", "Muscle Proteins", "Potassium Channels", "Randomized Controlled Trials as Topic", "Risk Factors"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85088500384", "SubjectAreas": [["Biochemistry, Genetics and Molecular Biology (all)", "BIOC", "1300"], ["Agricultural and Biological Sciences (all)", "AGRI", "1100"], ["Multidisciplinary", "MULT", "1000"]], "AuthorData": {"55789389000": {"Name": "Legault M.A.", "AuthorID": "55789389000", "AffiliationID": "60009507", "AffiliationName": "Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Pharmacogenomics Centre"}, "57196485679": {"Name": "Sandoval J.", "AuthorID": "57196485679", "AffiliationID": "60009507", "AffiliationName": "Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Pharmacogenomics Centre"}, "7003351244": {"Name": "Provost S.", "AuthorID": "7003351244", "AffiliationID": "60009507", "AffiliationName": "Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Pharmacogenomics Centre"}, "14031107300": {"Name": "Barhdadi A.", "AuthorID": "14031107300", "AffiliationID": "60009507", "AffiliationName": "Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Pharmacogenomics Centre"}, "36807712700": {"Name": "Perreault L.P.L.", "AuthorID": "36807712700", "AffiliationID": "60009507", "AffiliationName": "Universit\u00e9 de Montr\u00e9al Beaulieu-Saucier Pharmacogenomics Centre"}, "57211449671": {"Name": "de Denus S.", "AuthorID": "57211449671", "AffiliationID": "60009507", "AffiliationName": "Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al"}, "35399980400": {"Name": "Tardif J.C.", "AuthorID": "35399980400", "AffiliationID": "60009507", "AffiliationName": "Department of medicine, Universit\u00e9 de Montr\u00e9al"}, "57218517579": {"Name": "Dub\u00e9i M.P.", "AuthorID": "57218517579", "AffiliationID": "60009507", "AffiliationName": "Department of medicine, Universit\u00e9 de Montr\u00e9al"}, "55236808400": {"Name": "Shah S.", "AuthorID": "55236808400", "AffiliationID": "60022148", "AffiliationName": "Institute of Cardiovascular Science, University College London"}, "57193905922": {"Name": "Lumbers R.T.", "AuthorID": "57193905922", "AffiliationID": "60004093", "AffiliationName": "Bart\u2019s Heart Centre, St. Bartholomew\u2019s Hospital"}, "24470439400": {"Name": "Tyl B.", "AuthorID": "24470439400", "AffiliationID": "60017173", "AffiliationName": "Cardiovascular Center for Therapeutic Innovation, Institut de Recherches Internationales Servier"}}}